Philip N. Hawkins, PhD, FRCP, FRCPath | Authors

AL Amyloidosis: New Drugs and Tests, but Old Challenges

February 09, 2012

Immunoglobulin light chain (AL) amyloidosis develops in 2% of individuals with monoclonal plasma cell dyscrasias. In this issue of ONCOLOGY, Drs. Gertz and Dispenzieri discuss AL amyloidosis, highlighting progress in the field along with outstanding challenges.